Mylan Inc. company logo

# 1st Gen Model Mylan Inc. Pharmaceutical preparations

  • $39.01Last close price
    at 22-jun-2017
  • Subscribe >> Deal exit on
    June 23, 2017
    Deal entry on
    June 23, 2017
  • 2.61%Expected margin
  • 64.29% successful of 70 deals


Model's trade recommendations 2.25% Return for period

-4.08% Annual return

$20.51B Market Cap

β 1.23  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 2.25%
52wk return -7.96%
52wk Range
Sortino ratio -0.20
Sharpe ratio -0.16
Norm. RMSE 0.56%
Downside risk 14.49%
Volatility 17.67%
  • BUY Analysts consensus recommendation

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Mylan Inc. (MYL) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for MYL model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 532M
P/E 7.59
Shares Outstanding 536M
% Held by Insiders 0.69%
% Held by Institutions 69.89%
EPS (last reported FY) $4.89
EPS (last reported Q) $0.93
EPS, estimated (last reported Q) $0.92
Total revenues $11 B
Net income $0 B